BioCentury
ARTICLE | Finance

Southern fixins

Why Hatteras is sticking to biotechs in the southeastern U.S.

September 7, 2015 7:00 AM UTC

Armed with two new LPs, Hatteras Venture Partners is continuing its search for early stage assets in the southeastern U.S., which the firm sees as one of the few remaining regions where high-quality science has not been thoroughly combed through by other venture investors.

On Aug. 24 the firm announced a $90 million first closing for Hatteras Venture Partners V, a planned $150 million fund that will invest in therapeutics, devices, diagnostics and healthcare IT companies. ...